Key result
Selective aldosterone synthase inhibitors reduce systolic blood pressure by ~11 mmHg vs placebo.
Why the study?
Uncontrolled and resistant hypertension remain major clinical challenges despite multidrug therapy. The magnitude and consistency of benefit from selective aldosterone synthase inhibitors at clinically relevant doses in placebo-controlled trials remained uncertain.
Do selective aldosterone synthase inhibitors (lorundrostat 50 mg or baxdrostat 2 mg once daily) reduce systolic blood pressure compared with placebo in adults with uncontrolled or resistant hypertension?
Meta-Analysis
Double-blind
Randomized
Do selective aldosterone synthase inhibitors (lorundrostat 50 mg or baxdrostat 2 mg once daily) reduce systolic blood pressure compared with placebo in adults with uncontrolled or resistant hypertension?
Selective aldosterone synthase inhibitors (lorundrostat 50 mg and baxdrostat 2 mg daily) provide consistent short-term reductions in systolic (-10.81 mmHg) and diastolic (-4.92 mmHg) blood pressure without excess serious adverse events in uncontrolled or resistant hypertension.
Answers are grounded in this paper and cite their sources.
Supports aldosterone synthase inhibitors for resistant hypertension; confirms pooled efficacy and warrants outcome trials.
Background: Uncontrolled and resistant hypertension remain major clinical challenges and are associated with high cardiovascular and renal risk despite multidrug therapy. Selective aldosterone synthase inhibitors target aldosterone-driven treatment resistance, but the magnitude and consistency of benefit at clinically relevant doses in placebo-controlled trials remain uncertain. Methods: We performed a PRISMA-based systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials evaluating lorundrostat or baxdrostat in adults with uncontrolled or resistant hypertension receiving background antihypertensive therapy. To improve cross-trial comparability and minimize shared-placebo bias, analyses were restricted to prespecified clinically relevant doses (lorundrostat 50 mg once daily; baxdrostat 2 mg once daily). The primary outcome was the change in systolic blood pressure (SBP) from baseline. Secondary outcomes included diastolic blood pressure (DBP), estimated glomerular filtration rate (eGFR), blood pressure response rates, serious adverse events, treatment discontinuation, overall adverse events, and hyperkalemia when available. Random-effects models were constructed using restricted maximum likelihood with Hartung-Knapp adjustment. Results: Six randomized comparisons were included, comprising three lorundrostat and three baxdrostat comparisons. Both agents significantly reduced SBP versus placebo. Lorundrostat reduced SBP by a pooled mean difference (MD) of -9.47 mmHg (95% CI, -14.47 to -4.47; I 2 =0%), and baxdrostat reduced SBP by -11.61 mmHg (95% CI, -17.45 to -5.76; I 2 =0%). In the pooled analysis, selective aldosterone synthase inhibition reduced SBP by -10.81 mmHg (95% CI, -13.21 to -8.40; I 2 =0%). The pooled MD for DBP was -4.92 mmHg (95% CI, -6.79 to -3.05; I 2 ≈0%). No statistically significant effect on eGFR was observed. Blood pressure response rates, serious adverse events, treatment discontinuation, and overall adverse events did not differ significantly from placebo. Hyperkalemia was reported, but placebo-comparator data were inconsistently available, limiting comparative synthesis. Conclusions: In adults with uncontrolled or resistant hypertension, selective aldosterone synthase inhibitors at clinically relevant doses were associated with consistent short-term reductions in SBP and DBP with minimal heterogeneity and no excess signal in serious adverse events or treatment discontinuation. These findings support continued late-stage development of this therapeutic class, while longer-term studies are needed to better define renal and potassium safety.
No takes yet. Share an insight, caveat, or question.
Daneii et al. (2026) conducted a meta-analysis in Uncontrolled or resistant hypertension. Selective aldosterone synthase inhibitors (lorundrostat or baxdrostat) vs. Placebo on background antihypertensive therapy was evaluated on Change in systolic blood pressure (SBP) from baseline (MD -10.81 mmHg, 95% CI -13.21 to -8.40). Selective aldosterone synthase inhibitors reduced systolic blood pressure by 10.81 mmHg vs placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: